Marie Bosslett, Assistant Editor

At a Dermatology Times Case-Based Roundtable in Las Vegas, clinicians compared topical corticosteroids, newer nonsteroidal agents, and systemic therapy across adult and adolescent AD cases.

Oral JAK1 povorcitinib shows manageable adverse acne and strong responses even after biologic failure, offering an alternative to injections.

This review of the latest dermatological studies includes insights on JAKs in severe HS, reactive cutaneous capillary endothelial proliferation in esophageal SCC, PN treatment preferences, and more.

Martina Porter, MD, highlights phase 3 data showing povorcitinib boosts hidradenitis suppurativa responses by week 3 and sustains gains to 54 weeks in refractory patients.

See how precision biologics—dupilumab, IL-13/IL-31 blockers, JAK inhibitors, and omalizumab—change treatment for atopic dermatitis and chronic spontaneous urticaria.

In this episode, Miles Harrison and Brian Pilcher, PhD, explain investigational ECM injectables that aim to restore tissue scaffold for wound healing and address post–GLP-1 skin quality changes beyond fillers.

FDA clears Labcorp’s NGS tissue test to quickly spot BRAF V600E/K melanoma, guiding targeted BRAF/MEK therapy selection in days.

HS microbiome studies fuel probiotic hype, but a new review finds evidence too thin for routine use and highlights key research gaps.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Does facial massage with a gua sha improve skin or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

New oral TYK2 inhibitor shows rapid PASI 75/90 skin clearance in phase 2 plaque psoriasis study, with encouraging safety.

Obesity may blunt biologic psoriasis gains, according to a 4,200‑patient meta‑analysis showing lower PASI responses, but weight alone shouldn’t drive drug choice.

Absci's ABS-201 posts early phase 1 safety and long half-life, while new data show prolactin-receptor blockade may revive hair growth in AGA.

The European Commission greenlights upadacitinib for severe alopecia areata, with phase 3 data showing rapid scalp, brow and lash regrowth; US decision still pending.

Conexeu is advancing its ECM-regenerating tissue tech, targeting wound care via FDA 510(k) and eyeing aesthetics, reconstruction, and beyond.

This review of the latest dermatological studies includes insights on fibromyalgia in rosacea patients, isotretinoin use and suicidality in adolescents, patient-centered teledermatology, and more.

Conexeu is developing an injectable, thermosensitive ECM scaffold to remodel skin after rapid weight loss, aiming beyond fillers to restore tissue structure.

Explore the top dermatology conferences and meetings happening this month and let us know which ones you'll be attending!

FDA reviews phase 3 results and expanded BOTOX Cosmetic use for masseter prominence and nonsurgical jawline contouring, potentially becoming the first neurotoxin approved in the US for this indication.

This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.

As we wrap up UV Safety Awareness Month, Kathleen Suozzi, MD, explains warning signs of sun damage, sunscreen myths, and new year-round protection tools—plus the newly FDA-approved bemotrizinol.

Learn more about the in-depth topics covered in the July 2026 digital issue of Dermatology Times.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Dermatology Times is looking back on the top stories in dermatology from the month of July.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of July.

Phase 1 results show Bambusa Therapeutics’ BBT001 quickly reduces atopic dermatitis and itch, sustains type 2 biomarker suppression, and may enable quarterly dosing.

As we wrap up July, explore the new sunscreen ingredient approval, debunk summer skin care myths, and learn how UV damage and therapies are shaping skin cancer prevention today.

Catch up on all of our coverage from this year's Society for Pediatric Dermatology annual meeting.

Learn from Adnan Mir, MD, PhD, on how better biopsies and direct lab communication help APPs and dermatopathologists boost pediatric skin diagnoses and outcomes.

Lawrence Eichenfield, MD, presented phase 3 results showing lebrikizumab boosts skin clearance, eases itch, and looks safe for infants through teens with moderate to severe atopic dermatitis.